Champlain Investment Partners LLC Increases Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Champlain Investment Partners LLC raised its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 14.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,800,073 shares of the company’s stock after buying an additional 358,821 shares during the quarter. Champlain Investment Partners LLC owned about 6.72% of SI-BONE worth $39,145,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of SIBN. Rhumbline Advisers grew its stake in SI-BONE by 1.5% during the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after acquiring an additional 852 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in SI-BONE by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock worth $205,000 after buying an additional 1,105 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in SI-BONE by 7.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after buying an additional 1,372 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after acquiring an additional 2,108 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Insider Transactions at SI-BONE

In other news, CEO Laura Francis sold 10,048 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at $6,074,567.50. This trade represents a 2.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,093 shares of company stock worth $299,558. 3.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SIBN has been the topic of several recent research reports. Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday. Finally, Morgan Stanley cut their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

SI-BONE Trading Up 2.2 %

NASDAQ SIBN opened at $12.56 on Friday. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $21.70. The stock has a market capitalization of $526.77 million, a P/E ratio of -13.65 and a beta of 1.22. The firm’s 50-day moving average is $13.72 and its two-hundred day moving average is $14.21. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.